Singapore team develops PAI-1-targeting nanobody against peritoneal metastasis
Start here
A National Cancer Center Singapore-led team analyzed 397 ascites samples using multi-omics methods and identified PAI-1 and S100A10 as key tumor-promoting proteins in the peritoneal metastasis microenvironment of cancer of the abdominal lining. Building on this, they developed E8, a nanobody targeting PAI-1, as a candidate approach for treating late-stage peritoneal metastatic cancer. The work, reported in regulatory and industry coverage in October 2026, links fluid-driven tumor promotion to a defined molecular target. Open questions include how E8 performs in further preclinical and clinical testing, whether targeting PAI-1 alone suffices given the role of S100A10, and which patient populations would benefit most.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- Medical XpressPickResearch team develops novel nanobody targeting tumor-fueling fluid to treat late-stage cancer of abdominal lining
A team led by the National Cancer Center Singapore (NCCS) performed multi-omics analysis of 397 ascites samples and identified PAI-1 and S100A10 as key tumor-promoting proteins in the peritoneal metastasis microenvironment. Based on this, they developed E8, a nanobody targeting PAI-1.
Coverage and heat for this story
Reports so far 1·Heat now 5·Peak heat 10 (Oct 20 16:00)·Reports, 24h 0
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.